Cytokine IL-36γ Improves CAR T Cell Functionality and Induces Endogenous Anti-Tumor Response

Chimeric antigen receptor (CAR) T cell therapy has shown remarkable responses in B cell malignancies. However, many patients suffer from limited response and tumor relapse due to lack of persisting CAR T cells and immune escape. These clinical challenges have compromised the long-term efficacy of CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xinghuo, Daniyan, Anthony F., Lopez, Andrea V., Purdon, Terence J., Brentjens, Renier J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680719/
https://www.ncbi.nlm.nih.gov/pubmed/32447345
http://dx.doi.org/10.1038/s41375-020-0874-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680719/
https://www.ncbi.nlm.nih.gov/pubmed/32447345
http://dx.doi.org/10.1038/s41375-020-0874-1

Ejemplares similares